MX2024011338A - Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes. - Google Patents
Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes.Info
- Publication number
- MX2024011338A MX2024011338A MX2024011338A MX2024011338A MX2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A MX 2024011338 A MX2024011338 A MX 2024011338A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- small molecules
- crbm
- moiety
- target
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 230000001588 bifunctional effect Effects 0.000 title abstract 2
- 150000003384 small molecules Chemical class 0.000 title abstract 2
- 230000008684 selective degradation Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 abstract 2
- 108010006523 asialoglycoprotein receptor Proteins 0.000 abstract 2
- 230000000593 degrading effect Effects 0.000 abstract 2
- 210000003494 hepatocyte Anatomy 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 101150050927 Fcgrt gene Proteins 0.000 abstract 1
- -1 FcÎ3RI Proteins 0.000 abstract 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 abstract 1
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 abstract 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 abstract 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 abstract 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 108091005485 macrophage scavenger receptors Proteins 0.000 abstract 1
- 108020004084 membrane receptors Proteins 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 102000014452 scavenger receptors Human genes 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/695,645 US12485178B2 (en) | 2018-04-09 | 2022-03-15 | Bifunctional small molecules to target the selective degradation of circulating proteins |
| PCT/US2023/064470 WO2023178202A2 (en) | 2022-03-15 | 2023-03-15 | Bifunctional small molecules to target the selective degradation of circulating proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011338A true MX2024011338A (es) | 2024-12-06 |
Family
ID=88024440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011338A MX2024011338A (es) | 2022-03-15 | 2024-09-13 | Moléculas bifuncionales pequeñas para dirigir la degradación selectiva de proteínas circulantes. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4493222A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025509730A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240166514A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119255822A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023236291A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL315579A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024011338A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023178202A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス， インコーポレイテッド | Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート |
| WO2025219911A1 (en) * | 2024-04-16 | 2025-10-23 | Biohaven Therapeutics Ltd. | Treatment of diseases with monoclonal antibody drugs and molecular degraders |
| WO2025248469A1 (en) * | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | TREATMENT OF IgG-RELATED DISEASES |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016332900C1 (en) * | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| CA3134765A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| CA3134610A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| EP3897747A4 (en) * | 2018-12-19 | 2022-12-07 | The Board of Trustees of the Leland Stanford Junior University | BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS |
| MX2022009419A (es) * | 2020-01-31 | 2022-08-25 | Avilar Therapeutics Inc | Compuestos de union al asgpr para la degradacion de proteinas extracelulares. |
-
2023
- 2023-03-15 JP JP2024555107A patent/JP2025509730A/ja active Pending
- 2023-03-15 WO PCT/US2023/064470 patent/WO2023178202A2/en not_active Ceased
- 2023-03-15 EP EP23771648.5A patent/EP4493222A2/en active Pending
- 2023-03-15 AU AU2023236291A patent/AU2023236291A1/en active Pending
- 2023-03-15 CN CN202380040388.5A patent/CN119255822A/zh active Pending
- 2023-03-15 IL IL315579A patent/IL315579A/en unknown
- 2023-03-15 KR KR1020247034017A patent/KR20240166514A/ko active Pending
-
2024
- 2024-09-13 MX MX2024011338A patent/MX2024011338A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240166514A (ko) | 2024-11-26 |
| CN119255822A (zh) | 2025-01-03 |
| WO2023178202A2 (en) | 2023-09-21 |
| JP2025509730A (ja) | 2025-04-11 |
| WO2023178202A3 (en) | 2023-10-26 |
| AU2023236291A1 (en) | 2024-10-03 |
| IL315579A (en) | 2024-11-01 |
| EP4493222A2 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023178202A3 (en) | Bifunctional small molecules to target the selective degradation of circulating proteins | |
| MX2025012651A (es) | Moléculas pequeñas bifuncionales para dirigirse a la degradación selectiva de proteínas circulantes | |
| Brandina et al. | Enolase takes part in a macromolecular complex associated to mitochondria in yeast | |
| AR080942A1 (es) | Produccion de proteinas heteromultimericas | |
| DK1652258T3 (da) | Membran-elektrode-enhed til vandelektrolyse | |
| WO2020142672A3 (en) | Anti-tcr antibody molecules and uses thereof | |
| DK1846974T3 (da) | Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse | |
| GB9822576D0 (en) | Membrane | |
| EA201000490A1 (ru) | Антигенсвязывающие белки, связывающиеся с человеческим белком gm-csf | |
| TW200735447A (en) | Laminated electrolyte membrane for solid polymer fuel cells, membrane-electrode combine and fuel cells | |
| WO2002061105A3 (en) | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) | |
| BR122019022434B8 (pt) | método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular | |
| NO20073797L (no) | Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) | |
| Jiang et al. | Synthetic engineering of a new biocatalyst encapsulating [NiFe]-hydrogenases for enhanced hydrogen production | |
| ATE537188T1 (de) | Serumalbuminbindende proteine | |
| EA200700751A1 (ru) | Способы и композиции для улучшения продуцирования рекомбинантного белка | |
| DK1931704T3 (da) | Frembringelse og rensning af IL-29 | |
| TW200623499A (en) | Polymer electrolyte material, polymer electrolyte component, membrane electrolyte complex, and polymer electrolyte fuel cell | |
| WO2009139863A3 (en) | Chimeric small molecules for the recruitment of antibodies to cancer cells | |
| GEAP202316382A (en) | Anti-cd122 antibodies and uses thereof | |
| Werner et al. | Performing in vitro sumoylation reactions using recombinant enzymes | |
| GB2464888A (en) | Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system | |
| MX2023008909A (es) | Proteínas de unión a psma y usos de estas. | |
| CY1118782T1 (el) | Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια | |
| MX2025009325A (es) | Composiciones dirigidas al antigeno de membrana especifico de prostata (psma) y metodos para fabricar y usar las mismas |